Literature DB >> 28033526

Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT.

Gunnar Wichmann1, Anne Krüger2, Andreas Boehm2, Marlen Kolb2, Mathias Hofer2, Milos Fischer2, Stefan Müller2, Sandra Purz3, Patrick Stumpp4, Osama Sabri3, Andreas Dietz2, Regine Kluge3.   

Abstract

BACKGROUND: Long-term laryngectomy-free (LFS), tumour-specific (TSS) and overall survival (OS) is achieved by non-surgical larynx preservation (LP) only in a proportion of patients with locally advanced laryngeal or hypopharyngeal cancer. A score facilitating decision-making after 1 cycle induction chemotherapy (IC-1) may improve LFS and TSS.
METHODS: Early response to IC-1 with TPF ± cetuximab was assessed in 52 patients using endoscopic tumour staging for selecting total laryngectomy for non-responders with endoscopic tumour surface shrinkage <30% versus induction chemotherapy plus radiotherapy (IC + RT) for responders. Computed tomography (CT)-based volumetry was used to assess volumes of primary tumour, neck nodes and their sum; maximum and mean standardised uptake value (SUVmax, SUVmean) were measured by 18F-FDG-PET/CT. Baseline and residual values after IC-1 were calculated and correlated with LFS, TSS and OS.
RESULTS: After IC-1, 39/52 patients (75%) were early responders. Early response predicted complete response to IC + RT (p = 8.48 × 10-9). Early laryngectomised non-responders and responders with endoscopic tumour surface shrinkage > 70% had best OS. Significant independent predictors for LFS in responders are number of CT-staged suspect positive neck nodes (N+), residual primary tumour volume, residual total tumour volume and the ratio of residual SUVmax and SUVmean (resSUVmax/resSUVmean). Our LFS-score combines >2N+, residual primary tumour volume > 20%, residual total tumour volume > 5.6 mL and resSUVmax/resSUVmean > 1.51 weighted by their hazard ratio (12, 6, 5 and 4); LFS-score ≤ 16 predicts increased LFS, OS and TSS (p < 0.05).
CONCLUSION: LFS-score ≤ 16 identifies in responders to IC-1 the patients with maximum benefit of non-surgical LP achieving long-term LFS. Even more importantly, a LFS-score > 16 defines patients unsuitable for LP applying the TPF/TP IC + RT protocol.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (18)F-FDG; Decision-making; Early response evaluation; HNSCC; Head and neck cancer; Hypopharyngeal cancer; Induction chemotherapy; Laryngeal cancer; Larynx preservation; PET/CT

Mesh:

Substances:

Year:  2016        PMID: 28033526     DOI: 10.1016/j.ejca.2016.11.013

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Meta-analysis of diffusion-weighted imaging for predicting locoregional failure of chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Authors:  Qiming Zhou; Fangfang Zeng; Yao Ding; Clifton D Fuller; Jihong Wang
Journal:  Mol Clin Oncol       Date:  2017-11-15

Review 2.  Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers.

Authors:  Łukasz Boguszewicz
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

3.  Histometabolic Tumor Imaging of Hypoxia in Oral Cancer: Clinicopathological Correlation for Prediction of an Aggressive Phenotype.

Authors:  Grégoire B Morand; Martina A Broglie; Paul Schumann; Martin W Huellner; Niels J Rupp
Journal:  Front Oncol       Date:  2020-08-27       Impact factor: 6.244

4.  Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer.

Authors:  Jonas Werner; Martin W Hüllner; Niels J Rupp; Alexander M Huber; Martina A Broglie; Gerhard F Huber; Grégoire B Morand
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

5.  Magnetic resonance imaging-derived radiomic signature predicts locoregional failure after organ preservation therapy in patients with hypopharyngeal squamous cell carcinoma.

Authors:  Che-Yu Hsu; Shih-Min Lin; Ngan Ming Tsang; Yu-Hsiang Juan; Chun-Wei Wang; Wei-Chung Wang; Sung-Hsin Kuo
Journal:  Clin Transl Radiat Oncol       Date:  2020-08-31

6.  [Larynx preservation up to T4 laryngeal cancer?]

Authors:  Gerhard Dyckhoff; Rolf Warta; Christel Herold-Mende; Peter K Plinkert; Heribert Ramroth
Journal:  HNO       Date:  2022-05-24       Impact factor: 1.330

7.  Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer.

Authors:  Michael Beck; Sabine Semrau; Marlen Haderlein; Antoniu-Oreste Gostian; Julius Hartwich; Sarina Müller; Annett Kallies; Carol-Immanuel Geppert; Miriam Schonath; Florian Putz; Udo Gaipl; Benjamin Frey; Marc Saake; Heinrich Iro; Michael Uder; Arndt Hartmann; Torsten Kuwert; Rainer Fietkau; Markus Eckstein; Markus Hecht
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

8.  Development of a Human Leukocyte Antigen Score to Predict Progression-Free Survival in Head and Neck Squamous Cell Carcinoma Patients.

Authors:  Gunnar Wichmann; Claudia Lehmann; Cindy Herchenhahn; Marlen Kolb; Mathias Hofer; Susanne Wiegand; Andreas Dietz
Journal:  Front Oncol       Date:  2018-05-17       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.